IRA Already Impacting Merck & Co. BD Decisions, CEO Davis Says
Executive Summary
Merck & Co. CEO Rob Davis said the company is already factoring policy changes from the Inflation Reduction Act into its business development decisions.
You may also be interested in...
Merck Acquires Much Needed Diversification With $10.8bn Prometheus Buy
Merck will reduce its dependence on oncology and expand in immunology, adding a Phase III-ready TL1A inhibitor for IBD that could reach the market a few years ahead of losing exclusivity for Keytruda.
IRA Drug Pricing Implications Impact Pharma Views On Deal Terms, Valuations
Pharma business development executives and venture capital investors shared their thoughts on the Inflation Reduction Act at Biocom’s Global Life Science Partnering and Investor Conference in San Diego.
For Some Biotechs, IRA Remains Intangible – For Now
Some biotech leaders say IRA policies don’t feel consequential yet, though small companies could face impacts from R&D and M&A decision making at big pharmas.